Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of [14C] Milvexian in Healthy Males
NCT03939702Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milvexian in thrombosis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of [14C]BMS-986177, Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC(INF)) of [14C]BMS-986177 and 14 more. Started May 2019; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03939702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939702.